Past Meeting | Keystone Symposia

This meeting took place in the past. Here is a list of meetings that are related:
There are no records.

Web Desc
Challenges of Global Vaccine Development Organizer(s): Margaret Liu, Paul-Henri Lambert and Sir Gustav Nossal Date: October 08 - 13, 2007 Location: Cape Town Conference Centre, Cape Town, South Africa Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation and the Wellcome Trust Summary of Meeting: Despite the tremendous impact of vaccines to save countless lives, significant scientific and technical barriers exist that limit both their effectiveness against many diseases and their utilization, resulting in millions of needless deaths and substantial morbidity particularly in the developing world. Even with the large increase of our understanding of host immune responses, the sequencing of pathogen genomes, and other technological advances, important hurdles remain for developing and deploying vaccines for a variety of diseases. The goals of this meeting will be to bring together scientists, physicians and students from the developed and developing world to discuss the advances in (1) understanding the generation of effective systemic and mucosal immunity at a cellular and organ system level, (2) new technologies for prophylactic and therapeutic immunization, including those useful for resource-poor settings, (3) understanding the unique requirements to stimulate immunity in early childhood, (4) pre-clinical models, and (5) correlates of protection. Global Health Travel Award Deadline: May 7 2007 Scholarship Deadline: June 6 2007 Discounted Abstract Deadline: June 6 2007 Abstract Deadline: July 11 2007 Discounted Registration Deadline: August 8 2007 We gratefully acknowledge additional support for this conference from: We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements: BD Medical Pharmaceutical Systems Genentech, Inc. GlaxoSmithKline Biologicals IOMAI Corporation We gratefully acknowledge the generous grant for this conference provided by: National Institute of Allergy and Infectious Diseases (NIAID) Grant No. 1R13AI076090-01 We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: Click here to view more of these organizations Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds: Click here to view more of these organizations

Web Desc

Challenges of Global Vaccine Development

Organizer(s): Margaret Liu, Paul-Henri Lambert and Sir Gustav Nossal

Date: October 08 - 13, 2007
Location: Cape Town Conference Centre, Cape Town, South Africa

Part of the Keystone Symposia Global Health Series, Supported by the Bill & Melinda Gates Foundation and the Wellcome Trust

Summary of Meeting:

Despite the tremendous impact of vaccines to save countless lives, significant scientific and technical barriers exist that limit both their effectiveness against many diseases and their utilization, resulting in millions of needless deaths and substantial morbidity particularly in the developing world. Even with the large increase of our understanding of host immune responses, the sequencing of pathogen genomes, and other technological advances, important hurdles remain for developing and deploying vaccines for a variety of diseases. The goals of this meeting will be to bring together scientists, physicians and students from the developed and developing world to discuss the advances in (1) understanding the generation of effective systemic and mucosal immunity at a cellular and organ system level, (2) new technologies for prophylactic and therapeutic immunization, including those useful for resource-poor settings, (3) understanding the unique requirements to stimulate immunity in early childhood, (4) pre-clinical models, and (5) correlates of protection.

Global Health Travel Award Deadline: May 7 2007

Scholarship Deadline: June 6 2007

Discounted Abstract Deadline: June 6 2007

Abstract Deadline: July 11 2007

Discounted Registration Deadline: August 8 2007

We gratefully acknowledge additional support for this conference from:

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

BD Medical Pharmaceutical Systems

Genentech, Inc.

GlaxoSmithKline Biologicals

IOMAI Corporation

We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1R13AI076090-01

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program


Monday, October 08 \| 3:00PM - 7:30PM Registration Room: Strelitzia
Monday, October 08 \| 6:30PM - 7:30PM Welcome Reception Room: Day Restaurant
Monday, October 08 \| 7:30PM - 7:50PM Welcome and Orientation Room: Auditorium 2 Speaker 1 of 1 * Margaret A. Liu, ProTherImmune and Karolinska Institutet, USA The Unique Scientific and Real-World Challenges of Global Vaccine Development
Monday, October 08 \| 7:50PM - 8:30PM Keynote Address Speaker 1 of 1 Regina N. Rabinovich, ISGlobal, Spain / Harvard T.H. Chan School of Public Health, USA, Spain The Challenges of Translation of Vaccine Research into Impact
Tuesday, October 09 \| 7:00AM - 8:00AM Breakfast Room: Day Restaurant
Tuesday, October 09 \| 8:00AM - 11:30AM Population Differences in Immune Responses to Vaccines and I mplications for Childhood and Pandemic Diseases Room: Auditorium 2 Speaker 1 of 7 * Margaret A. Liu, ProTherImmune and Karolinska Institutet, USA
Tuesday, October 09 \| 8:00AM - 11:30AM Population Differences in Immune Responses to Vaccines and I mplications for Childhood and Pandemic Diseases Room: Auditorium 2 Speaker 2 of 7 * Gustav Nossal, University of Melbourne, Australia
Tuesday, October 09 \| 8:00AM - 11:30AM Population Differences in Immune Responses to Vaccines and I mplications for Childhood and Pandemic Diseases Room: Auditorium 2 Speaker 3 of 7 * Paul-Henri Lambert, University of Geneva, Switzerland
Tuesday, October 09 \| 8:00AM - 11:30AM Population Differences in Immune Responses to Vaccines and I mplications for Childhood and Pandemic Diseases Room: Auditorium 2 Speaker 4 of 7 Myron M. Levine, University of Maryland School of Medicine, USA Differences in Immune Responses in Different Populations
Tuesday, October 09 \| 8:00AM - 11:30AM Population Differences in Immune Responses to Vaccines and I mplications for Childhood and Pandemic Diseases Room: Auditorium 2 Speaker 5 of 7 Hazel M. Dockrell, London School Hygiene & Tropical Medicine, UK BCG Vaccination Induces Different Immune Responses in Malawian and UK Vaccinees
Tuesday, October 09 \| 8:00AM - 11:30AM Population Differences in Immune Responses to Vaccines and I mplications for Childhood and Pandemic Diseases Room: Auditorium 2 Speaker 6 of 7 Willem A. Hanekom, Bill & Melinda Gates Foundation, USA BCG-Induced Immune Correlates of Protection Against Tuberculosis
Tuesday, October 09 \| 8:00AM - 11:30AM Population Differences in Immune Responses to Vaccines and I mplications for Childhood and Pandemic Diseases Room: Auditorium 2 Speaker 7 of 7 Anne E. Goldfeld, Children's Hospital Boston, Harvard Medical School, USA HIV/TB Host-Pathogen Interactions
Tuesday, October 09 \| 9:20AM - 9:40AM Coffee Break Room: Day Restaurant
Tuesday, October 09 \| 11:30AM - 12:00PM Poster Setup Room: Day Restaurant
Tuesday, October 09 \| 12:00PM - 2:00PM Luncheon with Grand Challenges in Global Health Meeting Room: Ballroom Speaker 1 of 4 Harold E. Varmus, Weill Cornell Medical College, USA
Tuesday, October 09 \| 12:00PM - 2:00PM Luncheon with Grand Challenges in Global Health Meeting Room: Ballroom Speaker 2 of 4 Bishop Desmond Tutu, Former Archbishop of Cape Town, South Africa
Tuesday, October 09 \| 12:00PM - 2:00PM Luncheon with Grand Challenges in Global Health Meeting Room: Ballroom Speaker 3 of 4 Graça Machel, South Africa
Tuesday, October 09 \| 12:00PM - 2:00PM Luncheon with Grand Challenges in Global Health Meeting Room: Ballroom Speaker 4 of 4 Tadataka Yamada, Mountain Field LLC, USA
Tuesday, October 09 \| 2:30PM - 4:30PM Workshop 1A Devoted to Specific Diseases that Overwhelm the Developing World: Malaria Room: Auditorium 2 Speaker 1 of 6 * Michal Fried, Seattle Biomedical Research Institute, USA
Tuesday, October 09 \| 2:30PM - 4:30PM Workshop 1A Devoted to Specific Diseases that Overwhelm the Developing World: Malaria Room: Auditorium 2 Speaker 2 of 6 * Stefan Kappe, Seattle BioMed, USA
Tuesday, October 09 \| 2:30PM - 4:30PM Workshop 1A Devoted to Specific Diseases that Overwhelm the Developing World: Malaria Room: Auditorium 2 Speaker 3 of 6 Dominic Kwiatkowski, Wellcome Trust Centre for Human Genetics, UK Learning from the Human Genome How Protective Immunity Against Malaria Works
Tuesday, October 09 \| 2:30PM - 4:30PM Workshop 1A Devoted to Specific Diseases that Overwhelm the Developing World: Malaria Room: Auditorium 2 Speaker 4 of 6 Patrick E. Duffy, NIAID, National Institutes for Health, USA Protective Immunity Against Severe Malaria in Young Children
Tuesday, October 09 \| 2:30PM - 4:30PM Workshop 1A Devoted to Specific Diseases that Overwhelm the Developing World: Malaria Room: Auditorium 2 Speaker 5 of 6 Adrian V. S. Hill, Jenner Institute, University of Oxford, UK Vectored Vaccines for Malaria
Tuesday, October 09 \| 2:30PM - 4:30PM Workshop 1A Devoted to Specific Diseases that Overwhelm the Developing World: Malaria Room: Auditorium 2 Speaker 6 of 6 Salim Abdulla, Ifakara Health Institute, Tanzania Malaria Vaccine Clinical Trials in Africa
Tuesday, October 09 \| 2:30PM - 4:30PM Workshop 2A on Vaccine Technologies: Stability of Vaccines Room: Roof Terrace Room Speaker 1 of 4 * Marie-Paule Kieny, World Health Organization, Switzerland
Tuesday, October 09 \| 2:30PM - 4:30PM Workshop 2A on Vaccine Technologies: Stability of Vaccines Room: Roof Terrace Room Speaker 2 of 4 Colin R. Gardner, TransForm Pharmaceuticals, Inc., USA Increasing Vaccine Stability through Novel Technology
Tuesday, October 09 \| 2:30PM - 4:30PM Workshop 2A on Vaccine Technologies: Stability of Vaccines Room: Roof Terrace Room Speaker 3 of 4 Claire M. Coeshott, GlobeImmune, Inc., USA Thermostable Vaccines with Improved Stability at Non-Refrigerated Temperatures
Tuesday, October 09 \| 2:30PM - 4:30PM Workshop 2A on Vaccine Technologies: Stability of Vaccines Room: Roof Terrace Room Speaker 4 of 4 Yoshikazu Yuki, Institute of Medical Science, Japan Development of Needle- and Cold-Chain-Free Vaccine: Rice-Based Oral Vaccine
Tuesday, October 09 \| 4:30PM - 5:00PM Coffee Available Room: Day Restaurant
Tuesday, October 09 \| 5:00PM - 7:30PM Effector vs. Memory Responses Room: Auditorium 2 Speaker 1 of 6 * Margaret A. Liu, ProTherImmune and Karolinska Institutet, USA
Tuesday, October 09 \| 5:00PM - 7:30PM Effector vs. Memory Responses Room: Auditorium 2 Speaker 2 of 6 * Carolyn Williamson, University of Cape Town, South Africa
Tuesday, October 09 \| 5:00PM - 7:30PM Effector vs. Memory Responses Room: Auditorium 2 Speaker 3 of 6 Rafi Ahmed, Emory University School of Medicine, USA Manipulating Regulatory T Cell in the Development of Vaccines or Translating Innate Immunity into Immunologic Memory: Implications for Vaccine Development
Tuesday, October 09 \| 5:00PM - 7:30PM Effector vs. Memory Responses Room: Auditorium 2 Speaker 4 of 6 Rudolf A. Manz, Deutsches Rheuma-Forschungszentrum, Germany Plasma Cell Niches: Molecular Determinants of Long-Lived Plasma Cells
Tuesday, October 09 \| 5:00PM - 7:30PM Effector vs. Memory Responses Room: Auditorium 2 Speaker 5 of 6 Kenneth Smith, University of Cambridge, UK The Inhibitory Fc Receptor FcgammaRIIb, Immune Responses, Autoimmunity and Malaria
Tuesday, October 09 \| 5:00PM - 7:30PM Effector vs. Memory Responses Room: Auditorium 2 Speaker 6 of 6 George M. Shaw, University of Pennsylvania, USA Identification of the Transmitted HIV-1 Envelope and Its Evolution in Acute and Early Human Infection
Tuesday, October 09 \| 7:30PM - 8:30PM Social Hour with Lite Bites Room: Day Restaurant
Tuesday, October 09 \| 8:00PM - 10:00PM Poster Session 1 Room: Day Restaurant
Wednesday, October 10 \| 7:00AM - 8:00AM Breakfast Room: Day Restaurant
Wednesday, October 10 \| 8:00AM - 11:30AM Innate and Adaptive Immune Responses/Adjuvants Room: Auditorium 2 Speaker 1 of 7 * Marie-Paule Kieny, World Health Organization, Switzerland
Wednesday, October 10 \| 8:00AM - 11:30AM Innate and Adaptive Immune Responses/Adjuvants Room: Auditorium 2 Speaker 2 of 7 * Souleymane Mboup, Universite Cheikh Anta DIOP, Senegal
Wednesday, October 10 \| 8:00AM - 11:30AM Innate and Adaptive Immune Responses/Adjuvants Room: Auditorium 2 Speaker 3 of 7 Paul-Henri Lambert, University of Geneva, Switzerland Towards Effective and Safe Vaccines: Assessing the Risk-Benefit Ratio of Activating Innate Immunity
Wednesday, October 10 \| 8:00AM - 11:30AM Innate and Adaptive Immune Responses/Adjuvants Room: Auditorium 2 Speaker 4 of 7 Alan Aderem, Center for Infectious Disease Research, USA A Systems Approach to Vaccine Development
Wednesday, October 10 \| 8:00AM - 11:30AM Innate and Adaptive Immune Responses/Adjuvants Room: Auditorium 2 Speaker 5 of 7 Eyal Raz, University of California, San Diego, USA Irradiated Pathogens to Activate Dendritic Cells via TLRs for the Induction of T Cell Responses
Wednesday, October 10 \| 8:00AM - 11:30AM Innate and Adaptive Immune Responses/Adjuvants Room: Auditorium 2 Speaker 6 of 7 David C. Jackson, University of Melbourne, Australia The Use of Simple Synthetic Lipid Structures for Targeting Different Vaccine Cargos to Dendritic Cells
Wednesday, October 10 \| 8:00AM - 11:30AM Innate and Adaptive Immune Responses/Adjuvants Room: Auditorium 2 Speaker 7 of 7 Peter L. Andersen, Statens Serum Institut, Denmark TB Vaccine - Pre/Post Exposure
Wednesday, October 10 \| 9:20AM - 9:40AM Coffee Break Room: Day Restaurant
Wednesday, October 10 \| 11:00AM - 12:00PM Poster Setup Room: Day Restaurant
Wednesday, October 10 \| 11:30AM - 12:30PM Lunch Room: Day Restaurant
Wednesday, October 10 \| 12:30PM - 2:30PM Poster Session 2 Room: Day Restaurant
Wednesday, October 10 \| 2:30PM - 4:30PM Workshop 1B Devoted to Specific Diseases that Overwhelm the Developing World: Tuberculosis Vaccines Room: Auditorium 2 Speaker 1 of 8 * Martin Ota, Medical Research Council, Gambia
Wednesday, October 10 \| 2:30PM - 4:30PM Workshop 1B Devoted to Specific Diseases that Overwhelm the Developing World: Tuberculosis Vaccines Room: Auditorium 2 Speaker 2 of 8 * Jerald C. Sadoff, Crucell Vaccine Institute, Janssen Pharmaceutical Companies of Johnson & Johnson, Netherlands
Wednesday, October 10 \| 2:30PM - 4:30PM Workshop 1B Devoted to Specific Diseases that Overwhelm the Developing World: Tuberculosis Vaccines Room: Auditorium 2 Speaker 3 of 8 Tom H. M. Ottenhoff, Leiden University Medical Center, Netherlands Results from a Safety and Immunogenicity Clinical Trial with an Adjuvanted Ag85/ESAT6 Subunit Vaccine against Tuberculosis
Wednesday, October 10 \| 2:30PM - 4:30PM Workshop 1B Devoted to Specific Diseases that Overwhelm the Developing World: Tuberculosis Vaccines Room: Auditorium 2 Speaker 4 of 8 Helen McShane, Jenner Institute, UK MVA85A - An Update on Clinical Trials
Wednesday, October 10 \| 2:30PM - 4:30PM Workshop 1B Devoted to Specific Diseases that Overwhelm the Developing World: Tuberculosis Vaccines Room: Auditorium 2 Speaker 5 of 8 Greg D. Hussey, University of Cape Town, South Africa BCG and Clinical Trails
Wednesday, October 10 \| 2:30PM - 4:30PM Workshop 1B Devoted to Specific Diseases that Overwhelm the Developing World: Tuberculosis Vaccines Room: Auditorium 2 Speaker 6 of 8 Leander Grode, Vakzine Projekt Management, Germany Developing a TB Vaccine for Human Use
Wednesday, October 10 \| 2:30PM - 4:30PM Workshop 1B Devoted to Specific Diseases that Overwhelm the Developing World: Tuberculosis Vaccines Room: Auditorium 2 Speaker 7 of 8 Francois Spertini, Centre Hospitalier Universitaire Vaudois, Switzerland Safety and Immunogenicity of the Mtb72F/AS02A Tuberculosis Vaccine
Wednesday, October 10 \| 2:30PM - 4:30PM Workshop 1B Devoted to Specific Diseases that Overwhelm the Developing World: Tuberculosis Vaccines Room: Auditorium 2 Speaker 8 of 8 Megan Murray, Harvard Medical School, USA Modeling of Clinical TB
Wednesday, October 10 \| 2:30PM - 4:30PM Workshop 2B on Vaccine Technologies: Needle Free Delivery, A erosol Delivery and Nanoparticles Room: Roof Terrace Room Speaker 1 of 6 * Sujit Kuman Bhattacharya, National Institute of Cholera and Enteric Diseases, India
Wednesday, October 10 \| 2:30PM - 4:30PM Workshop 2B on Vaccine Technologies: Needle Free Delivery, A erosol Delivery and Nanoparticles Room: Roof Terrace Room Speaker 2 of 6 Ana Maria Henao-Restrepo, World Health Organization, Switzerland Development of a Measles Aerosol Vaccine
Wednesday, October 10 \| 2:30PM - 4:30PM Workshop 2B on Vaccine Technologies: Needle Free Delivery, A erosol Delivery and Nanoparticles Room: Roof Terrace Room Speaker 3 of 6 David A. Edwards, Harvard University, USA Dry Powder Nanoparticle Inhaled Aerosols for Needle-Free Vaccination
Wednesday, October 10 \| 2:30PM - 4:30PM Workshop 2B on Vaccine Technologies: Needle Free Delivery, A erosol Delivery and Nanoparticles Room: Roof Terrace Room Speaker 4 of 6 Robert E. Sievers, University of Colorado, USA Needle-Free Delivery of Stable, Respirable Dry Powder Measles Vaccine Formulations
Wednesday, October 10 \| 2:30PM - 4:30PM Workshop 2B on Vaccine Technologies: Needle Free Delivery, A erosol Delivery and Nanoparticles Room: Roof Terrace Room Speaker 5 of 6 James R. Baker Jr., University of Michigan, USA Naoemulsions as Adjuvants for Nasal-Spray Vaccines
Wednesday, October 10 \| 2:30PM - 4:30PM Workshop 2B on Vaccine Technologies: Needle Free Delivery, A erosol Delivery and Nanoparticles Room: Roof Terrace Room Speaker 6 of 6 David D. Lo, University of California, Riverside, USA Development of a Targeted Mucosal Vaccine Delivery Technology
Wednesday, October 10 \| 4:30PM - 5:00PM Coffee Available Room: Day Restaurant
Wednesday, October 10 \| 5:00PM - 7:30PM Neonatal and Infant Immunity Room: Auditorium 2 Speaker 1 of 5 * Claire-Anne Siegrist, University of Geneva, Switzerland Challenges and Perspectives for Optimal Early Life Vaccine Responses
Wednesday, October 10 \| 5:00PM - 7:30PM Neonatal and Infant Immunity Room: Auditorium 2 Speaker 2 of 5 Lorne A. Babiuk, University of Alberta, Canada Linking Innate and Specific Immunity to Develop Single-Dose Vaccines for Neonates
Wednesday, October 10 \| 5:00PM - 7:30PM Neonatal and Infant Immunity Room: Auditorium 2 Speaker 3 of 5 Victoria J. Philbin, USA Distinct Function of Toll-Like Receptors (TLRs) in Human Neonatal Antigen-Presenting Cells: Unique Potential of TLR8 Agonists as Neonatal Vaccine Adjuvents
Wednesday, October 10 \| 5:00PM - 7:30PM Neonatal and Infant Immunity Room: Auditorium 2 Speaker 4 of 5 Martha Sedegah, Naval Medical Research Center, USA Immunological Responses of Neonates and Infants to DNA-Based Vaccines
Wednesday, October 10 \| 5:00PM - 7:30PM Neonatal and Infant Immunity Room: Auditorium 2 Speaker 5 of 5 Mustafa Akkoyunlu, US Food and Drug Administration, USA Differences in Adult and Neonatal BAFF/APRIL System: Implications for Polysaccharide Vaccines
Thursday, October 11 \| 7:00AM - 8:00AM Breakfast Room: Day Restaurant
Thursday, October 11 \| 8:00AM - 11:15AM Vaccines Impacting on Microbial Ecology Room: Auditorium 2 Speaker 1 of 7 * Luis Jodar, International Vaccine Institute, South Korea
Thursday, October 11 \| 8:00AM - 11:15AM Vaccines Impacting on Microbial Ecology Room: Auditorium 2 Speaker 2 of 7 * Stefan H. E. Kaufmann, Max Planck Institute for Infection Biology, Berlin, Germany
Thursday, October 11 \| 8:00AM - 11:15AM Vaccines Impacting on Microbial Ecology Room: Auditorium 2 Speaker 3 of 7 Richard Adegbola, Bill & Melinda Gates Foundation, USA Haemophilus influnzae type b (Hib) Conjugate Vaccine: Clinical Trials and Implementation of an Effective Routine Hib Immunization Programme in The Gambia
Thursday, October 11 \| 8:00AM - 11:15AM Vaccines Impacting on Microbial Ecology Room: Auditorium 2 Speaker 4 of 7 Helena Käyhty, National Public Health Institute, Finland The Use of Nasopharyngeal Carriage as an End Point for Efficacy Trials and Registration and Use of New Pneumococcal Vaccine Formulations
Thursday, October 11 \| 8:00AM - 11:15AM Vaccines Impacting on Microbial Ecology Room: Auditorium 2 Speaker 5 of 7 Shabir Madhi, National Institute for Communicable Diseases, South Africa Pneumococcal Conjugate Vaccine in Developing Countries: Potential for Addressing the Ignored Epidemic
Thursday, October 11 \| 8:00AM - 11:15AM Vaccines Impacting on Microbial Ecology Room: Auditorium 2 Speaker 6 of 7 Jonathan Carapetis, Telethon Institute for Child Health Research, Australia Global Burden of Group A Streptococcal Disease, and Progress in Vaccine Development
Thursday, October 11 \| 8:00AM - 11:15AM Vaccines Impacting on Microbial Ecology Room: Auditorium 2 Speaker 7 of 7 John D. Clemens, International Vaccine Institute, South Korea New Approaches to the Assessment of Vaccine Herd Immunity and Herd Protection
Thursday, October 11 \| 9:20AM - 9:40AM Coffee Break Room: Day Restaurant
Thursday, October 11 \| 11:15AM - 11:30AM Special Announcement Dr. Jose Esparza, Senior Advisor on HIV Vaccines for the Bill & Melinda Gates Foundation, will announce an important new development in the growth of the Global HIV Vaccine Enterprise, an alliance of independent organizations around the world dedicated to accelerating the development of a preventive HIV vaccine. Originally proposed in 2003, the purpose of the Enterprise is to build consensus in the HIV vaccine field on scientific priorities, mobilize new resources to implement these priorities, and facilitate the rapid sharing of information that can advance the field as a whole. To date, the Enterprise has mobilized more than $750 million in support of its scientific plan.
Thursday, October 11 \| 11:30AM - 12:00PM Poster Setup Room: Day Restaurant
Thursday, October 11 \| 11:30AM - 12:30PM Lunch Room: Day Restaurant
Thursday, October 11 \| 12:30PM - 2:30PM Poster Session 3 Room: Day Restaurant
Thursday, October 11 \| 2:30PM - 4:30PM Workshop 1C Devoted to Specific Diseases that Overwhelm the Developing World: HIV Vaccines Room: Auditorium 2 Speaker 1 of 6 * Glenda E. Gray, South African Medical Research Council, South Africa
Thursday, October 11 \| 2:30PM - 4:30PM Workshop 1C Devoted to Specific Diseases that Overwhelm the Developing World: HIV Vaccines Room: Auditorium 2 Speaker 2 of 6 Blake Ball, University of Manitoba, Canada Comprehensive Studies of Mechanisms of HIV Resistance in Highly Exposed Uninfected Women
Thursday, October 11 \| 2:30PM - 4:30PM Workshop 1C Devoted to Specific Diseases that Overwhelm the Developing World: HIV Vaccines Room: Auditorium 2 Speaker 3 of 6 George K. Lewis, University of Maryland, USA Targeting Co-receptor Steps for Protective Immunity Against HIV-1
Thursday, October 11 \| 2:30PM - 4:30PM Workshop 1C Devoted to Specific Diseases that Overwhelm the Developing World: HIV Vaccines Room: Auditorium 2 Speaker 4 of 6 Hongkui Deng, Peking University, China Development of Novel Mouse Models for HIV and HCV Infection
Thursday, October 11 \| 2:30PM - 4:30PM Workshop 1C Devoted to Specific Diseases that Overwhelm the Developing World: HIV Vaccines Room: Auditorium 2 Speaker 5 of 6 Michael Ott, Hannover Medical School, Germany Novel Mouse Models for Testing HIV and HCV Vaccines
Thursday, October 11 \| 2:30PM - 4:30PM Workshop 1C Devoted to Specific Diseases that Overwhelm the Developing World: HIV Vaccines Room: Auditorium 2 Speaker 6 of 6 Rudi Balling, Centre for Systems Biology Luxembourg, University of Luxembourg, Luxembourg Novel Mouse Models for Testing HIV and HCV Vaccines
Thursday, October 11 \| 2:30PM - 4:30PM Workshop 1D: Enteric Pathogens Room: Roof Terrace Room Speaker 1 of 4 * John D. Clemens, International Vaccine Institute, South Korea
Thursday, October 11 \| 2:30PM - 4:30PM Workshop 1D: Enteric Pathogens Room: Roof Terrace Room Speaker 2 of 4 Firdausi Qadri, International Centre for Diarrhoeal Disease Research, Bangladesh Mucosal Immunity to Common Enteric Pathogens and Relevance to Vaccine Development
Thursday, October 11 \| 2:30PM - 4:30PM Workshop 1D: Enteric Pathogens Room: Roof Terrace Room Speaker 3 of 4 Sujit Kuman Bhattacharya, National Institute of Cholera and Enteric Diseases, India Field Trial of Enteric Vaccines in Kolkata
Thursday, October 11 \| 2:30PM - 4:30PM Workshop 1D: Enteric Pathogens Room: Roof Terrace Room Speaker 4 of 4 Gregory M. Glenn, Novavax, USA Transcutaneous Immunization with LT: Development of a Needle-Free Vaccine Patch
Thursday, October 11 \| 4:30PM - 5:00PM Coffee Available Room: Day Restaurant
Thursday, October 11 \| 5:00PM - 7:30PM Mucosal and Dermal Vaccines and Immunity Room: Auditorium 2 Speaker 1 of 5 * Gustav Nossal, University of Melbourne, Australia
Thursday, October 11 \| 5:00PM - 7:30PM Mucosal and Dermal Vaccines and Immunity Room: Auditorium 2 Speaker 2 of 5 Charles J. Arntzen, Biodesign Institute, Arizona State University, USA Progress in Plant-Made Vaccines
Thursday, October 11 \| 5:00PM - 7:30PM Mucosal and Dermal Vaccines and Immunity Room: Auditorium 2 Speaker 3 of 5 Robin Shattock, Imperial College London, UK Novel Antigen Design and Delivery for Mucosal Protection Against HIV-1 Infection
Thursday, October 11 \| 5:00PM - 7:30PM Mucosal and Dermal Vaccines and Immunity Room: Auditorium 2 Speaker 4 of 5 Roy Curtiss III, Arizona State University, USA A Live Recombinant Attenuated Salmonella Anti-Pneumococcal Vaccine for Newborns
Thursday, October 11 \| 5:00PM - 7:30PM Mucosal and Dermal Vaccines and Immunity Room: Auditorium 2 Speaker 5 of 5 Béhazine Combadiere, Centre d'Immunologie et des Maladies Infectieuses, France Short Talk: Follicular Targeting: From Skin Explant to Transcutaneous Vaccination in Humans
Friday, October 12 \| 7:00AM - 8:00AM Breakfast Room: Day Restaurant
Friday, October 12 \| 8:00AM - 11:45AM Correlates of Immunity in Pre-Clinical Models and Clinical S tudies Room: Auditorium 2 Speaker 1 of 7 * Glenda E. Gray, South African Medical Research Council, South Africa
Friday, October 12 \| 8:00AM - 11:45AM Correlates of Immunity in Pre-Clinical Models and Clinical S tudies Room: Auditorium 2 Speaker 2 of 7 Stefan H. E. Kaufmann, Max Planck Institute for Infection Biology, Berlin, Germany Towards Characterization of Protective Immunity against TB
Friday, October 12 \| 8:00AM - 11:45AM Correlates of Immunity in Pre-Clinical Models and Clinical S tudies Room: Auditorium 2 Speaker 3 of 7 Markus G. Manz, University Hospital Zürich, Switzerland A Mouse Model to Evaluate Live Attenuated Vaccine Candidates
Friday, October 12 \| 8:00AM - 11:45AM Correlates of Immunity in Pre-Clinical Models and Clinical S tudies Room: Auditorium 2 Speaker 4 of 7 Britta E. Wahren, Karolinska Institute, Sweden Progress of the HIV Vaccine Phase I/II Immunogenicity Study (HIVIS Project) in Dar es Salaam, Tanzania: HIV-1 DNA Plasmid Prime and MVA Boost
Friday, October 12 \| 8:00AM - 11:45AM Correlates of Immunity in Pre-Clinical Models and Clinical S tudies Room: Auditorium 2 Speaker 5 of 7 Sarah L. Rowland-Jones, Oxford University, UK Long-Term Non-Progression with HIV Infection: Lessons from HIV-2
Friday, October 12 \| 8:00AM - 11:45AM Correlates of Immunity in Pre-Clinical Models and Clinical S tudies Room: Auditorium 2 Speaker 6 of 7 Carolyn Williamson, University of Cape Town, South Africa Multigene Human Immunodeficiency Virus Type 1 Subtype C DNA and Modified Vaccinia Ankara (MVA) Vaccine
Friday, October 12 \| 8:00AM - 11:45AM Correlates of Immunity in Pre-Clinical Models and Clinical S tudies Room: Auditorium 2 Speaker 7 of 7 * Gary J. Nabel, Sanofi, USA Development and Evaluation of a T-Cell Based Multi-Clade AIDS Vaccine
Friday, October 12 \| 9:20AM - 9:40AM Coffee Break Room: Day Restaurant
Friday, October 12 \| 2:30PM - 4:30PM Workshop 3: Issues for Introducing Vaccines to Developing Co untries: Coordination of Clinical Trials in Different Populations and Markets, Access, Vaccine Cost, Affordability, and Financing Room: Auditorium 2 Speaker 1 of 6 * José G. Esparza, Bill & Melinda Gates Foundation, USA
Friday, October 12 \| 2:30PM - 4:30PM Workshop 3: Issues for Introducing Vaccines to Developing Co untries: Coordination of Clinical Trials in Different Populations and Markets, Access, Vaccine Cost, Affordability, and Financing Room: Auditorium 2 Speaker 2 of 6 Bernard Fourie, Medicine in Need, South Africa Challenges to Vaccine Access in High-Burden Settings
Friday, October 12 \| 2:30PM - 4:30PM Workshop 3: Issues for Introducing Vaccines to Developing Co untries: Coordination of Clinical Trials in Different Populations and Markets, Access, Vaccine Cost, Affordability, and Financing Room: Auditorium 2 Speaker 3 of 6 Duncan Steele, PATH, USA Delivering Rotavirus Vaccines to Impact the Millennium Development Goals
Friday, October 12 \| 2:30PM - 4:30PM Workshop 3: Issues for Introducing Vaccines to Developing Co untries: Coordination of Clinical Trials in Different Populations and Markets, Access, Vaccine Cost, Affordability, and Financing Room: Auditorium 2 Speaker 4 of 6 Jean Stephenne, GlaxoSmithKline Biologicals, Belgium GSK Issues for Global Vaccine Manufacturers
Friday, October 12 \| 2:30PM - 4:30PM Workshop 3: Issues for Introducing Vaccines to Developing Co untries: Coordination of Clinical Trials in Different Populations and Markets, Access, Vaccine Cost, Affordability, and Financing Room: Auditorium 2 Speaker 5 of 6 Luis Jodar, International Vaccine Institute, South Korea Translational Research to Assist Policy Decisions about Introducing New Vaccines into Developing Countries
Friday, October 12 \| 2:30PM - 4:30PM Workshop 3: Issues for Introducing Vaccines to Developing Co untries: Coordination of Clinical Trials in Different Populations and Markets, Access, Vaccine Cost, Affordability, and Financing Room: Auditorium 2 Speaker 6 of 6 Carl E. Frasch, Frasch Biologics Consulting, USA Strategies for Production of Pneumococcal Conjugate Vaccines in and for Developing Countries
Friday, October 12 \| 2:30PM - 4:30PM Workshop 2C on Vaccine Technologies and Other Novel Technolo gies: Mucosal and Dermal Vaccines Room: Roof Terrace Room Speaker 1 of 4 * Britta E. Wahren, Karolinska Institute, Sweden Novel Delivery Devices and Approaches for Immunization
Friday, October 12 \| 2:30PM - 4:30PM Workshop 2C on Vaccine Technologies and Other Novel Technolo gies: Mucosal and Dermal Vaccines Room: Roof Terrace Room Speaker 2 of 4 * Rachel Chikwamba, Council for Scientific and Industrial Research (CSIR), South Africa Plant Derived Vaccines for Mucosal Delivery
Friday, October 12 \| 2:30PM - 4:30PM Workshop 2C on Vaccine Technologies and Other Novel Technolo gies: Mucosal and Dermal Vaccines Room: Roof Terrace Room Speaker 3 of 4 Edward P. Rybicki, University of Cape Town, South Africa Plant-Produced Vaccines: Promise and Reality
Friday, October 12 \| 2:30PM - 4:30PM Workshop 2C on Vaccine Technologies and Other Novel Technolo gies: Mucosal and Dermal Vaccines Room: Roof Terrace Room Speaker 4 of 4 Philippe E. Laurent, Becton Dickinson, France Evaluation of the Clinical Performance of BD™ Microinjection System for Intradermal Vaccine Delivery
Friday, October 12 \| 4:30PM - 5:00PM Coffee Available Room: Day Restaurant
Friday, October 12 \| 5:00PM - 6:30PM Novel Approaches to Immunity Room: Auditorium 2 Speaker 1 of 5 * Margaret A. Liu, ProTherImmune and Karolinska Institutet, USA
Friday, October 12 \| 5:00PM - 6:30PM Novel Approaches to Immunity Room: Auditorium 2 Speaker 2 of 5 * Gustav Nossal, University of Melbourne, Australia
Friday, October 12 \| 5:00PM - 6:30PM Novel Approaches to Immunity Room: Auditorium 2 Speaker 3 of 5 Reinhard Kurth, Ernst Schering Foundation, Germany Novel Approaches to Flu Vaccine Development
Friday, October 12 \| 5:00PM - 6:30PM Novel Approaches to Immunity Room: Auditorium 2 Speaker 4 of 5 Abraham L. Sonenshein, Tufts University, School of Medicine, USA Bacterial Spores as Heat-Stable Vaccine Delivery Systems
Friday, October 12 \| 5:00PM - 6:30PM Novel Approaches to Immunity Room: Auditorium 2 Speaker 5 of 5 Lennart Hammarström, Karolinska Institute, Sweden Passive Immunity via Orally-Administered lactobacilli
Friday, October 12 \| 6:30PM - 7:30PM Concluding Keynote Address Room: Auditorium 2 Speaker 1 of 1 Anna-Lise Williamson, University of Cape Town, South Africa Vaccine Development: An Essential Part of Health Security in Africa
Friday, October 12 \| 7:30PM - 8:30PM Social Hour with Lite Bites Room: Day Restaurant
Friday, October 12 \| 8:00PM - 11:00PM Entertainment Room: Day Restaurant
Friday, October 12 \| 8:00PM - 11:00PM Cash Bar Room: Day Restaurant
Saturday, October 13 \| 10:25AM - 10:25AM Departure *Session Chair.